Tag: osteoporosis

1. Abaloparatide significantly reduced the risk of new vertebral and non-vertebral fractures compared with placebo. 2. Treatment with abaloparatide also resulted in higher bone mineral density (BMD) gains compared with placebo and teriparatide. Evidence Rating Level: 1 (Excellent) Study Rundown: Vertebral fractures disproportionately affect post-menopausal women, and lead to a lower quality of...
1. Based on a post-hoc analysis of the Women’s Health Initiative, post-menopausal women’s self-reported adherence to a Mediterranean diet was associated with lower risk of hip fractures, albeit with a small absolute risk reduction. 2. Although this was a post-hoc analysis, which decreases the reliability of the results, this does...
1. In this retrospective cohort study, two-thirds of new osteoporosis drug prescriptions were potentially inappropriate as diagnosis was based on non-International Society of Clinical Densitometry recommended sites. 2. Of these potentially inappropriate prescriptions, half were given to younger women without osteoporosis risk factors who may not have needed screening. Evidence Rating...
1. Hematopoietic stem cells (HSCs) were engineered to moderately overexpress platelet-derived growth factor (PDGF-BB), an important bone growth factor. 2. Mice transplanted with HSCs moderately overexpressing PDGF-BB showed increased levels of the bone formation marker alkaline phosphatase (ALP), bone formation, and bone strength compared to untreated mice or mice...
1. Subclinical hyperthyroidism was found to be associated with an increased risk of hip and any fractures in this meta-analysis, but was not associated with spine or nonspine fractures. 2. Subclinical hypothyroidism was not associated with hip, any, spine, or nonspine fracture risk in this meta-analysis. Evidence Rating Level: 1 (Excellent) Study...
1. A single dose of zoledronic acid improved bone mineral density over 2 years in frail elderly women. 2. Rates of fracture or mortality did not differ significantly between zoledronic acid treatment and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Although as many as 85% of frail elderly adults living...
1. Based on the results of the trial, there was no difference in the rates of osteoporotic fractures between the group receiving statin therapy compared to the group receiving placebo. 2. Additionally, rising levels of high-sensitivity C-reactive protein (hs-CRP), which is an inflammatory marker related to cardiovascular disease, was not...

Patient Basics: Osteoporosis

Originally published by Harvard Health. What Is It? Osteoporosis is a bone disorder. The bones become thinner. They lose their strength and are more likely to break. People with osteoporosis have a higher risk of fractures. Bones can fracture even during everyday movements, such as bending or coughing. The most common osteoporotic fractures...
1. This systematic review demonstrated that in postmenopausal women with osteoporosis, bisphosphonates, denosumab and teriparatide were associated with a significantly reduced risk of vertebral and nonvertebral fractures, compared to placebo. 2. The comparative effectiveness of the different pharmacological agents available to treat osteoporosis is unclear. Evidence Rating Level: 1 (Excellent)...
1. Scaffolds coated with a polyelectrolyte multilayer (PEM) film released growth factors (GFs) with individual temporal control during bone reconstruction.  2. PEM films containing platelet-derived growth factor-BB (PDGF-BB) and bone morphogenetic protein-2 (BMP-2) promoted robust new bone formation that recapitulated native bone in the rat.  Evidence Rating Level: 2 (Good)  Study Rundown:...